Briefing Pharmather Psychedelics

PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will be raising C$10.0 million via a financing conducted exclusively by H.C. Wainwright. The financing will see the company sell a total of 15.6 million units of the company price at $0.64 per each, with each …

Briefing Bright Minds Biosciences News Psychedelics

Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022

Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing the company’s proprietary agonist BMB-101 to the investigational new drug stage enabling safety and toxicology studies for its potential treatment of Dravet syndrome. The biotech firm is selecting BMB-101 as the lead drug candidate in …

Analyst Estimate Briefing Numinus Wellness Inc Psychedelics

Numinus Wellness: Eight Capital Initiates With $1.10 Price Target

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The fourth company initiated on this note is Numinus Wellness Inc. (TSXV: NUMI), with a C$1.10 12-month price target and buy rating while referring to the firm as “a diversified operator.” …

Analyst Estimate Briefing Bright Minds Biosciences News Psychedelics

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The last company to be initiated on is Bright Minds Biosciences (CSE: DRUG), with an C$11.50 price target, or a 67% upside and a buy rating. Eight Capital headlines the note, …

Analyst Estimate Briefing Mind Medicine Psychedelics

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. They say that after a large influx of capital and “a growing body of clinical trial data on the use of psychedelics and related substances demonstrating a remarkable degree of …

Analyst Estimate Briefing Field Trip Health Psychedelics

Eight Capital Initiates Coverage On Field Trip Health With $10.20 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The third company on this list is Field Trip Health (CSE: FTRP) with a C$10.20 12-month price target and buy rating. Field Trip Health currently has 3 analysts covering the …

Briefing Bright Minds Biosciences Ian McDonald Psychedelics The Daily Dive Video Series

Explainer: Anti Alzheimer’s, Dravet Syndrome, Epilepsy & Addiction Drugs – The Daily Dive

On today’s Daily Dive, Cassandra welcomes back Ian McDonald, CEO of Bright Minds Biosciences (CSE: DRUG). He shares the promising results of the company’s proprietary BMB-101 drug to treat a rare form of epilepsy, Dravet Syndrome. The chief officer also talks about the firm’s plan to list on the Nasdaq, the common misconceptions on psychedelics, …